|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.56 HKD | -1.77% |
|
-6.55% | -26.06% |
| Apr. 15 | 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia | MT |
| Apr. 12 | 3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication | CI |
3SBio Inc. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 3,091.36 million compared to CNY 3,107.14 million a year ago. Net income was CNY 954.52 million compared to CNY 898.91 million a year ago.
Basic earnings per share from continuing operations was CNY 0.39 compared to CNY 0.35 a year ago. Diluted earnings per share from continuing operations was CNY 0.37 compared to CNY 0.34 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -26.06% | 1.69B | |
| -5.99% | 83.66B | |
| +2.76% | 40.41B | |
| -24.88% | 28.26B | |
| +53.61% | 24.53B | |
| -8.08% | 16.82B | |
| -33.74% | 13.39B | |
| -16.63% | 11.75B | |
| -11.19% | 11.69B | |
| -2.25% | 8.13B |
3SBIO INC. 
